Cidara Therapeutics Inc.
Clinical trials sponsored by Cidara Therapeutics Inc., explained in plain language.
Now part of
Merck & Co., Inc.
MRK
NYSE
A biotech developing antifungal therapies, subsidiary of Merck.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antiviral shot could boost flu protection when given with vaccine Results expected Dec 2026 (estimated)
- One-Shot flu prevention? new drug aims to protect High-Risk groups all season Results expected Jun 2027 (estimated)
- Yearly flu shot alternative? new drug tested for Long-Term safety Results expected Jul 2027 (estimated)